RU98108602A - Succinimide and maleimide cytokine inhibitors - Google Patents
Succinimide and maleimide cytokine inhibitorsInfo
- Publication number
- RU98108602A RU98108602A RU98108602/04A RU98108602A RU98108602A RU 98108602 A RU98108602 A RU 98108602A RU 98108602/04 A RU98108602/04 A RU 98108602/04A RU 98108602 A RU98108602 A RU 98108602A RU 98108602 A RU98108602 A RU 98108602A
- Authority
- RU
- Russia
- Prior art keywords
- carbon atoms
- substituted
- alkyl
- phenyl
- compound according
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 title 1
- 229960002317 succinimide Drugs 0.000 title 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 21
- -1 carbetoxy Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000004429 atoms Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 5
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000001602 bicycloalkyls Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 239000005977 Ethylene Substances 0.000 claims 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 3
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000005293 bicycloalkoxy group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 101710031992 pRL90232 Proteins 0.000 claims 2
- 101710035540 plaa2 Proteins 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
Claims (16)
где R1 представляет собой -CH2-, -CH2CO- или -CO-;
R2 и R3, взятые вместе, представляют собой:
(i) этилен незамещенный или замещенный одним или несколькими алкилами, состоящими из 1 - 10 атомов углерода, или фенилом;
(ii) винилен, замещенный двумя заместителями, каждый из которых выбран независимо от другого из группы, состоящей из алкила с углеродной цепью из 1 - 10 атомов и фенила; или
(iii) двухвалентного циклоалкила с углеродной цепью из 5 - 10 атомов, незамещенного или замещенного одним или несколькими заместителями, каждый из которых выбран независимо от другого из группы, состоящей из: нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, незамещенного или замещенного алкилом, состоящим из 1 - 3 атомов углерода, ацетокси, карбокси, гидрокси, амино, замещенной аминогруппы, алкила, состоящего из 1 - 10 атомов углерода, алкокси, состоящего из 1 - 10 атомов углерода, норборнила, фенила или галогена;
R4 представляет:
(i) незамещенный алкил с прямой или разветвленной цепью из 4 - 8 атомов углерода;
(ii) циклоалкил или бициклоалкил, состоящий из 5 - 10 атомов углерода, незамещенный или замещенный одним или более заместителями, каждый из которых выбран независимо от другого из группы, состоящей из: нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, замещенной аминогруппы, алкила, с прямой или циклической цепью, состоящего из 1 - 10 атомов углерода, алкокси, состоящего из 1 - 10 атомов углерода, фенила или галогена;
(III) фенил, замещенный одним или несколькими заместителями, каждый из которых выбран независимо от другого из группы, состоящей из: нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, замещенного амино, алкила, состоящего из 1 - 10 атомов углерода, алкокси, состоящего из 1 - 10 атомов углерода, циклоалкила или бициклоалкила, состоящего из 3 - 10 атомов углерода, циклоалкокси или бициклоалкокси, состоящего из 3 - 10 атомов углерода, фенила или галогена; или
(iv) гетероцикл, состоящий из 4 - 10 атомов, включающий один или несколько гетероатомов, каждый из которых независимо выбран из N, O или S, незамещенный или замещенный одним или несколькими заместителями, каждый из которых выбран независимо от другого из группы, состоящей из: нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, замещенной аминогруппы, алкила, состоящего из 1 - 10 атомов углерода, алкокси, состоящего из 1 - 10 атомов углерода, фенила или галогена;
R5 представляет -COX, -CN, -CH2COX, алкил, состоящий из 1 - 5 атомов углерода, арил, -CH2OR, CH2арил, CH2ОН,
где Х представляет NH2, OH, NHR, R или OR6,
где R представляет низший алкил;
где R6 представляет алкил или бензил.1. Compounds of the formula:
where R 1 represents —CH 2 -, —CH 2 CO— or —CO—;
R 2 and R 3 taken together are:
(i) ethylene unsubstituted or substituted by one or more alkyls of 1 to 10 carbon atoms or phenyl;
(ii) vinylene substituted by two substituents, each of which is selected independently from the other from the group consisting of alkyl with a carbon chain of 1 to 10 atoms and phenyl; or
(iii) a divalent cycloalkyl with a carbon chain of 5 to 10 atoms, unsubstituted or substituted by one or more substituents, each of which is selected independently from the other from the group consisting of: nitro, cyano, trifluoromethyl, carbetoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl unsubstituted or substituted by an alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, a substituted amino group, an alkyl of 1 to 10 carbon atoms, an alkoxy of 1 to 10 carbon atoms, norbornyl, phenyl or halogen and;
R 4 represents:
(i) unsubstituted straight or branched chain alkyl of 4 to 8 carbon atoms;
(ii) cycloalkyl or bicycloalkyl, consisting of 5 to 10 carbon atoms, unsubstituted or substituted by one or more substituents, each of which is selected independently from the group consisting of: nitro, cyano, trifluoromethyl, carbetoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl, straight or cyclic chain, consisting of 1 to 10 carbon atoms, alkoxy, consisting of 1 to 10 carbon atoms, phenyl or halogen;
(III) phenyl substituted by one or more substituents, each selected independently from the other from the group consisting of: nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, cycloalkyl or bicycloalkyl of 3 to 10 carbon atoms, cycloalkoxy or bicycloalkoxy of 3 to 10 carbon atoms, phenyl or halogen; or
(iv) a heterocycle of 4 to 10 atoms, including one or more heteroatoms, each of which is independently selected from N, O or S, unsubstituted or substituted by one or more substituents, each of which is selected independently from the other from the group consisting of : nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl, consisting of 1 to 10 carbon atoms, alkoxy, consisting of 1 to 10 carbon atoms, phenyl or halogen;
R 5 is —COX, —CN, —CH 2 COX, alkyl of 1 to 5 carbon atoms, aryl, —CH 2 OR, CH 2 aryl, CH 2 OH,
where X represents NH 2 , OH, NHR, R or OR 6 ,
where R represents lower alkyl;
where R 6 represents alkyl or benzyl.
где R1 представляет собой -CH2-, -CH2CO- или -СО-;
R2 и R3, взятые вместе, представляют собой:
(i) незамещенный этилен, или замещенный одним или несколькими алкилами, состоящими из 1 - 10 атомов углерода, или фенил;
(ii) винилен, замещенный двумя заместителями, каждый из которых выбран независимо от другого из группы, состоящей из алкила с углеродной цепью из 1 - 10 атомов и фенила;
(iii) двухвалентного циклоалкила с углеродной цепью из 5 - 10 атомов, незамещенного или замещенного одним или несколькими заместителями, каждый из которых выбран независимо от другого из группы, состоящей из: нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, незамещенного или замещенного алкилом, состоящим из 1 - 3 атомов углерода, ацетокси, карбокси, гидрокси, амино, замещенной аминогруппы, алкила, состоящего из 1 - 10 атомов углерода, алкокси, состоящего из 1 - 10 атомов углерода, норборнила, фенила или галогена;
R4 представляет:
(i) незамещенный алкил с прямой или разветвленной цепью из 4 - 8 атомов углерода;
(ii) циклоалкил или бициклоалкил, состоящий из 5 - 10 атомов углерода, незамещенный или замещенный одним или более заместителями, каждый из которых выбран независимо от другого из группы, состоящей из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, замещенной аминогруппы, алкила, с прямой или циклической цепью, состоящего из 1 - 10 атомов углерода, алкокси, состоящего из 1 - 10 атомов углерода, фенила или галогена;
(iii) фенил, замещенный одним или несколькими заместителями, каждый из которых выбран независимо от другого из группы, состоящей из: нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, замещенного амино, алкила, состоящего из 1 - 10 атомов углерода, алкокси, состоящего из 1 - 10 атомов углерода, циклоалкила или бицикло-алкила, состоящего из 3 - 10 атомов углерода, циклоалкокси или бициклоалкокси, состоящего из 3 - 10 атомов углерода, фенила или галогена; или
(iv) гетероцикл, состоящий из 4 - 10 атомов, включающий один или несколько гетероатомов, каждый из которых независимо выбран из N, O или S, незамещенный или замещенный одним или несколькими заместителями, каждый из которых выбран независимо от другого из группы, состоящей из: нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, замещенной аминогруппы, алкила, состоящего из 1 - 10 атомов углерода, алкокси, состоящего из 1 - 10 атомов углерода, фенила или галогена;
R5 представляет -COX, -CN, -CH2COX, алкил, состоящий из 1 - 5 атомов углерода, арил, -CH2OR, CH2арил, CH2OH,
где X представляет NH2, OH, NHR, R или OR6,
где R представляет низший алкил; и
где R6 представляет алкил или бензил.10. A method of reducing TNFα levels in mammals, which comprises administering to them an effective amount of a compound of the formula:
where R 1 represents —CH 2 -, —CH 2 CO— or —CO—;
R 2 and R 3 taken together are:
(i) unsubstituted ethylene, or substituted by one or more alkyls of 1 to 10 carbon atoms, or phenyl;
(ii) vinylene substituted by two substituents, each of which is selected independently from the other from the group consisting of alkyl with a carbon chain of 1 to 10 atoms and phenyl;
(iii) a divalent cycloalkyl with a carbon chain of 5 to 10 atoms, unsubstituted or substituted by one or more substituents, each of which is selected independently from the other from the group consisting of: nitro, cyano, trifluoromethyl, carbetoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl unsubstituted or substituted by an alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, a substituted amino group, an alkyl of 1 to 10 carbon atoms, an alkoxy of 1 to 10 carbon atoms, norbornyl, phenyl or halogen and;
R 4 represents:
(i) unsubstituted straight or branched chain alkyl of 4 to 8 carbon atoms;
(ii) cycloalkyl or bicycloalkyl, consisting of 5 to 10 carbon atoms, unsubstituted or substituted by one or more substituents, each of which is independently selected from the group consisting of nitro, cyano, trifluoromethyl, carbetoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl , acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl, with a straight or cyclic chain, consisting of 1 to 10 carbon atoms, alkoxy, consisting of 1 to 10 carbon atoms, phenyl or halogen;
(iii) phenyl substituted by one or more substituents, each independently selected from the group consisting of: nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino , alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, cycloalkyl or bicycloalkyl of 3 to 10 carbon atoms, cycloalkoxy or bicycloalkoxy of 3 to 10 carbon atoms, phenyl or halogen ; or
(iv) a heterocycle of 4 to 10 atoms, including one or more heteroatoms, each of which is independently selected from N, O or S, unsubstituted or substituted by one or more substituents, each of which is selected independently from the other from the group consisting of : nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl, consisting of 1 to 10 carbon atoms, alkoxy, consisting of 1 to 10 carbon atoms, phenyl or halogen;
R 5 is —COX, —CN, —CH 2 COX, alkyl of 1 to 5 carbon atoms, aryl, —CH 2 OR, CH 2 aryl, CH 2 OH,
where X represents NH 2 , OH, NHR, R or OR 6 ,
where R represents lower alkyl; and
where R 6 represents alkyl or benzyl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/539,879 | 1995-10-06 | ||
US08/539,879 US5658940A (en) | 1995-10-06 | 1995-10-06 | Succinimide and maleimide cytokine inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU98108602A true RU98108602A (en) | 2000-03-27 |
RU2176242C2 RU2176242C2 (en) | 2001-11-27 |
Family
ID=24153040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98108602/04A RU2176242C2 (en) | 1995-10-06 | 1996-10-04 | SUCCINIMIDE AND MALEIMIDE INHIBITORS OF CYTOKINS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS OF INHIBITION OF TUMOR NECROSIS α-FACTOR |
Country Status (19)
Country | Link |
---|---|
US (1) | US5658940A (en) |
EP (1) | EP0862552B1 (en) |
JP (1) | JP3226546B2 (en) |
KR (1) | KR100345826B1 (en) |
AT (1) | ATE248145T1 (en) |
AU (1) | AU723915B2 (en) |
CA (1) | CA2233975C (en) |
CZ (1) | CZ105398A3 (en) |
DE (1) | DE69629716T2 (en) |
ES (1) | ES2206600T3 (en) |
FI (1) | FI119690B (en) |
HK (1) | HK1017885A1 (en) |
HU (1) | HUP9902034A3 (en) |
NZ (1) | NZ321001A (en) |
PL (1) | PL326063A1 (en) |
PT (1) | PT862552E (en) |
RU (1) | RU2176242C2 (en) |
SK (1) | SK44698A3 (en) |
WO (1) | WO1997012859A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA019749B1 (en) * | 2007-06-29 | 2014-06-30 | Джилид Сайэнс, Инк. | Antiviral compounds |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
ATE236872T1 (en) * | 1996-08-12 | 2003-04-15 | Celgene Corp | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN REDUCING CYTOKININ LEVELS |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
AU2006200033B8 (en) * | 1998-10-30 | 2008-09-11 | Celgene Corporation | Substituted phenethylsulfones and methods of reducing TNF-alpha levels |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
EP1198461A2 (en) * | 1999-07-15 | 2002-04-24 | Cytoclonal Pharmaceutics, Inc. | Method of designing tubulin polymerization stabilizers |
US7122666B2 (en) * | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US20010051348A1 (en) * | 2000-01-28 | 2001-12-13 | Lee Chee Wee | Novel ligands and methods for preparing same |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7491634B2 (en) * | 2006-04-28 | 2009-02-17 | Asm International N.V. | Methods for forming roughened surfaces and applications thereof |
GB0125658D0 (en) * | 2001-10-25 | 2001-12-19 | Ssl Int Plc | Medicaments |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
CA2481385A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1496878A4 (en) * | 2002-04-12 | 2007-12-26 | Celgene Corp | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
NZ536908A (en) * | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
US7220746B2 (en) * | 2002-08-10 | 2007-05-22 | Altana Pharma Ag | Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors |
US6774758B2 (en) * | 2002-09-11 | 2004-08-10 | Kalyan P. Gokhale | Low harmonic rectifier circuit |
EP1551385A4 (en) * | 2002-10-15 | 2008-10-22 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
BR0316002A (en) * | 2002-11-06 | 2005-09-13 | Celgene Corp | Methods of treating or preventing and controlling a myeloproliferative disease, reducing or preventing an adverse effect associated with the administration of a second active agent in a patient suffering from a myeloproliferative disease, and enhancing the therapeutic efficacy of a myeloproliferative disease treatment, composition. pharmaceutical and kit |
JP2006508131A (en) | 2002-11-06 | 2006-03-09 | セルジーン・コーポレーション | Methods and compositions using selective cytokine inhibitors for the treatment and management of cancer and other diseases |
WO2004054501A2 (en) * | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
CA2506232A1 (en) * | 2002-11-18 | 2004-06-03 | Celgene Corporation | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
AU2004293443A1 (en) | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc. | Indazole Compounds and methods of use thereof as protein kinase inhibitors |
JP2007532642A (en) * | 2004-04-14 | 2007-11-15 | セルジーン・コーポレーション | Use of selective cytokine inhibitors for the treatment and management of myelodysplastic syndromes and compositions containing the same |
MXPA06012279A (en) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension. |
US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
JP2008518924A (en) * | 2004-10-28 | 2008-06-05 | セルジーン・コーポレーション | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
EP1951229B1 (en) * | 2005-11-21 | 2013-07-10 | Mordechai Sharir | Succinimide derivatives as ocular hypotensive agents |
US8853257B2 (en) | 2005-11-21 | 2014-10-07 | Mordechai Sharir | Succinimide derivatives as ocular hypotensive agents |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
CA2718412A1 (en) * | 2008-03-24 | 2009-10-01 | Celgene Corporation | Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
US8092822B2 (en) * | 2008-09-29 | 2012-01-10 | Abbott Cardiovascular Systems Inc. | Coatings including dexamethasone derivatives and analogs and olimus drugs |
NZ594193A (en) | 2009-02-10 | 2013-09-27 | Celgene Corp | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
JP5937060B2 (en) | 2010-04-07 | 2016-06-22 | セルジーン コーポレイション | Method for treating respiratory viral infections |
US20110318741A1 (en) | 2010-06-15 | 2011-12-29 | Schafer Peter H | Biomarkers for the treatment of psoriasis |
CN103788076B (en) * | 2014-01-22 | 2015-06-03 | 山西大学 | Reagent and method for detecting cysteine |
EP3142663A1 (en) | 2014-05-16 | 2017-03-22 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
ES2749433T3 (en) | 2014-06-23 | 2020-03-20 | Celgene Corp | Apremilast for the treatment of liver disease or abnormal liver function |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
WO2017209161A1 (en) * | 2016-06-03 | 2017-12-07 | Jnc株式会社 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2852526A (en) * | 1955-05-03 | 1958-09-16 | Schering Corp | Substituted pyrrolidines |
GB1539817A (en) * | 1976-10-22 | 1979-02-07 | Ucb Sa | N-substituted lactams |
FR2418790A1 (en) * | 1978-03-02 | 1979-09-28 | Philagro Sa | NEW DERIVATIVES OF PYRROLIDINONE-2 AND HERBICIDE COMPOSITIONS CONTAINING THEM |
US4394369A (en) * | 1982-05-24 | 1983-07-19 | Fmc Corporation | Hydrogen peroxide process |
US4996199A (en) * | 1988-04-08 | 1991-02-26 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
GB9013142D0 (en) * | 1990-06-13 | 1990-08-01 | Ciba Geigy Ag | Chemical compounds useful as metal deactivators |
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
PT100441A (en) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | PIRROLIDINONES, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE |
US5204366A (en) * | 1991-06-10 | 1993-04-20 | American Cyanamid Company | 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
SK86997A3 (en) * | 1994-12-30 | 1998-01-14 | Celgene Corp | Imides/amides as immunotherapeutic agents, pharmaceutical composition and their use for reducing level of tnf-alpha |
-
1995
- 1995-10-06 US US08/539,879 patent/US5658940A/en not_active Expired - Lifetime
-
1996
- 1996-10-04 EP EP96936155A patent/EP0862552B1/en not_active Expired - Lifetime
- 1996-10-04 AU AU73873/96A patent/AU723915B2/en not_active Ceased
- 1996-10-04 DE DE69629716T patent/DE69629716T2/en not_active Expired - Lifetime
- 1996-10-04 PT PT96936155T patent/PT862552E/en unknown
- 1996-10-04 RU RU98108602/04A patent/RU2176242C2/en not_active IP Right Cessation
- 1996-10-04 CA CA002233975A patent/CA2233975C/en not_active Expired - Fee Related
- 1996-10-04 SK SK446-98A patent/SK44698A3/en unknown
- 1996-10-04 NZ NZ321001A patent/NZ321001A/en not_active IP Right Cessation
- 1996-10-04 AT AT96936155T patent/ATE248145T1/en not_active IP Right Cessation
- 1996-10-04 ES ES96936155T patent/ES2206600T3/en not_active Expired - Lifetime
- 1996-10-04 CZ CZ981053A patent/CZ105398A3/en unknown
- 1996-10-04 JP JP51442097A patent/JP3226546B2/en not_active Expired - Fee Related
- 1996-10-04 KR KR1019980702531A patent/KR100345826B1/en not_active IP Right Cessation
- 1996-10-04 WO PCT/US1996/015864 patent/WO1997012859A1/en active IP Right Grant
- 1996-10-04 PL PL96326063A patent/PL326063A1/en unknown
- 1996-10-04 HU HU9902034A patent/HUP9902034A3/en unknown
-
1998
- 1998-04-03 FI FI980776A patent/FI119690B/en active IP Right Grant
-
1999
- 1999-03-08 HK HK99100926A patent/HK1017885A1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA019749B1 (en) * | 2007-06-29 | 2014-06-30 | Джилид Сайэнс, Инк. | Antiviral compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU98108602A (en) | Succinimide and maleimide cytokine inhibitors | |
RU97112858A (en) | SUBSTITUTED IMIDES AS INHIBITORS | |
RU97112857A (en) | NEW IMMUNOTHERAPEUTIC ARILAMIDES | |
RU99113849A (en) | IMMUNOTHERAPEUTIC IMIDES / AMIDES AS A PDE IV INHIBITOR AND TNF | |
RU98105689A (en) | ALPHA TUMOR NECROSIS FACTOR INHIBITORS | |
EA199800882A1 (en) | Derivatives of Mixed Indazols, Their Use as Photophodiesterrase Inhibitors (PDE) IV and Obtaining Tumor Necrosis Factor (TNF) | |
RU2000102639A (en) | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD TO REDUCE TNFα LEVELS | |
RU98113943A (en) | IMIDES AS INHIBITORS OF PHOSPHODYESTERASE III (PDE III), PHOSPHODESTERASE IV (PDE IV) AND TUMOR NECROSIS FACTOR (TNF) | |
EA199801047A1 (en) | Mixed causal inlazole and their use as inhibitors of phosphodiesterrase (PDE) TYPE IV and the tumor necrosis factor (TNF) | |
RU94045915A (en) | Indole derivatives, method of their synthesis, pharmcomposition | |
DE60130023D1 (en) | TREATMENT OF THE SIDE EFFECTS OF STATINES | |
RU2000127751A (en) | ANTI-TUMOR MEDICINE | |
CA2208746A1 (en) | Novel immunotherapeutic aryl amides | |
RU2004130488A (en) | Pyrimidine derivatives | |
HUP9902034A2 (en) | Succinimide and maleimide cytokine inhibitors | |
KR890701562A (en) | Immunomodulatory Azas Pirans | |
KR910006241A (en) | Pyrimidine-4,6-dicarboxylic acid diamide, preparation method thereof, use thereof and medicament based on these compounds | |
DE3853577D1 (en) | Benzylidene-malononitrile derivatives for inhibiting proliferative processes in mammalian cells. | |
RU2000123169A (en) | BENZOTHIADIAZOLES AND THEIR DERIVATIVES | |
RU95114528A (en) | Agents having antigastrin action | |
RU94011232A (en) | Alkaline-earth metal salts, transient metal salts and ketocarboxylic acid transient metal complexes as corrosion inhibitors | |
RU97115107A (en) | BICYCLIC DERIVATIVES OF ISOTHYOTURES USED IN THERAPY | |
ATE67193T1 (en) | 6-PHENYL-PYRIDAZINE COMPOUNDS. | |
RU94036760A (en) | Triazine derivatives, their synthesis and use | |
RU97112903A (en) | IMID / AMIDE ETHERS, PHARMACEUTICAL COMPOSITION ON THE BASIS AND METHOD FOR REDUCING THE MONOGRAPHY LEVEL (TNFA) IN MAMMALS |